Back
GLP-1 for Men: How Physicians Apply the Trial Evidence
By GetOPT Review Team · September 06, 2026
Glucagon-like peptide 1 (GLP-1) receptor agonists work in men, and the major obesity trials included men in mixed-sex groups. However, those trials were not designed to establish a male-specific response. For you, the main considerations are age, starting health, body composition, adverse effects, testosterone, fertility goals, and follow-up. There is less evidence on whether outcomes or risks differ by sex and on how your prescriber should monitor your response over time.1-3 Your baseline panel and repeat labs supply what the trials did not.
Mechanism of GLP-1 Receptor Agonists
A GLP-1 receptor agonist activates the receptor for GLP-1, a hormone signal involved in appetite and blood glucose control. This activity can reduce appetite and food intake, which can produce weight loss over time.
Semaglutide acts at the GLP-1 receptor. Tirzepatide acts at the GLP-1 receptor and the receptor for glucose-dependent insulinotropic polypeptide (GIP). GIP is another hormone signal involved in the body’s response to food.4
These two medications should not be treated as interchangeable. They act through different receptor pathways, and the clinical trials reported different average outcomes. You can read more about semaglutide on the semaglutide weight-loss pillar.
The mechanism explains how these medications can support weight loss. It does not tell your prescriber which medication fits your medical history, goals, tolerance, or follow-up plan. The baseline visit is where that fit gets decided.
How the Trials Were Built and What That Means for Men
The strongest evidence for GLP-1 treatment comes from large trials that enrolled both women and men. Men were a minority in the major obesity trials, and none of those trials was designed to answer a men-only question.1,2,4
This distinction affects how you should read the results. The average weight-loss figures apply to the full study populations. They cannot establish that men will lose the same amount, lose weight at the same pace, or experience adverse effects at the same frequency.
A narrative review found that sex differences have been observed in glycemic control, weight reduction, and adverse-event frequency with GLP-1 receptor agonists. The review did not establish a consistent direction or size for those differences. It also reported that possible sex differences in cardiovascular outcomes remain under investigation.3
The evidence becomes thinner when the discussion moves from weight loss to male hormones, fertility, sexual function, or age-specific outcomes. Those questions deserve direct answers, but the major weight-loss trials were not built to provide them. Your own labs and follow-up data answer them for you, which is why baseline testing comes before the prescription.
Weight-Loss Results From the Major Trials
The major semaglutide and tirzepatide trials reported average percentage changes at fixed endpoints. They did not report a standard weekly rate or a guaranteed timeline for an individual man.
| Trial | Study Population | Endpoint | Average Weight Change |
|---|---|---|---|
| STEP 1 | 1,961 adults with overweight or obesity and without diabetes | 68 weeks | 14.9% reduction with semaglutide and 2.4% with placebo1 |
| SURMOUNT-1 | 2,539 adults with overweight or obesity | 72 weeks | Mean reductions ranged from 15.0% to 20.9% across tirzepatide groups, compared with 3.1% with placebo2 |
| SURMOUNT-5 | 751 adults in an open-label, controlled trial | 72 weeks | 20.2% reduction with tirzepatide and 13.7% with semaglutide4 |
These are group averages from mixed-sex populations. Your result may fall above or below an average, and a percentage does not tell you how much fat or lean tissue changed.
Weight is one data point. Your physician should read it alongside lean mass, hormones, and how you feel.
SURMOUNT-5 found greater average weight reduction with tirzepatide than semaglutide over 72 weeks.4 That trial supports a head-to-head comparison across its full population. It does not establish tirzepatide as the best GLP-1 for men.
Your prescriber has to connect the trial evidence to your baseline weight, body composition, medical history, current medications, tolerance, and treatment goals. The prescription starts the process. Your follow-up data shows whether the plan fits you.
Treatment Considerations for Men Over 50
Men over 50 need closer attention to body composition during weight loss. A falling scale weight cannot show whether you lost fat, lean tissue, or a combination of both.
A body-composition analysis came from a SURMOUNT-1 substudy that included 160 participants with scans at baseline and the end of the study. The substudy was 73% female.5 Its findings should therefore be applied carefully to men, especially when making claims about how much lean tissue a man may lose.
If you are in your fifties or sixties, your physician should track more than total pounds. Strength, activity, nutrition, and a useful measure of body composition provide context for the scale. Rapid weight change gives your physician another reason to watch muscle closely.
The full discussion belongs in the guide to GLP-1 medications and muscle loss. Your target should include the type of weight you are losing.
Testosterone and Male Fertility
The cited obesity trials do not establish how GLP-1 receptor agonists affect testosterone in men. They also do not establish an effect on male fertility, sperm production, sexual function, or age-specific hormone outcomes.1,2,4
That absence is an evidence gap. It does not prove benefit, harm, or no effect.
If testosterone symptoms are part of your reason for considering treatment, measure the relevant hormones and discuss the results with your physician. Do not infer your testosterone level from weight, libido, gym performance, or comments in an online forum. The testosterone replacement therapy overview explains how low testosterone is evaluated and where treatment may fit.
A panel that includes hormones measures the question directly. A standard range helps identify an abnormal result, while optimal interpretation considers your symptoms, body composition, and prior results. One testosterone value is only one part of that pattern.
A weight-loss trial cannot tell you how treatment will affect your fertility. Raise that goal at the baseline visit, and it shapes both the plan and the follow-up labs.
Safety and Physician Follow-Up
No source cited here establishes one GLP-1 medication as the safest choice for men. Men were included in the major trials, but the trials did not produce a male-specific safety ranking.1,2,4
The sex-differences review reported observed differences in adverse-event frequency. It did not establish which adverse effects are more common in men or how large any difference may be.3 You should therefore avoid treating a general side-effect list as a prediction of your experience.
Before treatment, your prescriber should establish a baseline that can be compared with later results. That review includes your weight history, body composition goals, existing conditions, current medications, symptoms, and relevant laboratory findings.
Follow-up should track several concrete areas:
- Weight trend: Your measurements show how you are responding across time.
- Body composition: Scale weight alone cannot separate changes in fat from changes in lean tissue.
- Treatment tolerance: New or worsening symptoms can change whether the current plan remains appropriate.
- Nutrition and activity: Reduced appetite can change how much you eat, while your training affects how your physician interprets strength and body-composition changes.
- Hormone or fertility concerns: These require direct discussion and measurement because the obesity trials do not settle them.
A prescription without follow-up leaves your physician with no trend to interpret. One weight measurement is a data point. Repeated measurements show whether the treatment is moving you toward your goal.
Medication price is a separate part of the decision. The GLP-1 cost guide explains the line items that can affect what you pay without turning the treatment decision into a price comparison.
The Opt Take on GLP-1 for Men
Decisions about GLP-1 treatment as part of a weight-loss program should begin with your baseline. A panel of 55+ biomarkers gives your physician data across hormones, inflammation, cardiovascular risk, and other measures. Your physician reads those results against your weight history, symptoms, current medications, existing conditions, and body composition goals. Testosterone results and fertility goals belong in that review.
The treatment plan is built around your numbers.
Repeat blood panels and physician consultations every three to four months show how those numbers changed. Your physician can then adjust the treatment plan as your response and goals change. This makes GLP-1 care an ongoing physician-led process with a measurable baseline and follow-up data.
Get started: Begin with Opt Health, where a physician reads your labs, builds your plan, and adjusts it over the loop.
Frequently Asked Questions
Yes. Men were enrolled in the large semaglutide and tirzepatide obesity trials, and those mixed-sex trials found substantial average weight reduction across the full study populations.1,2,4
The trials were not designed to calculate a separate treatment effect for men. You can conclude that the medications function in men. You cannot use these sources to predict that your response will match the overall trial average or that men and women respond identically.
Your own trend provides the useful answer. Your prescriber can compare your baseline with your weight, body composition, symptoms, and laboratory results during treatment.
No trial cited here identifies a best GLP-1 for men. SURMOUNT-5 found greater average weight reduction with tirzepatide than semaglutide over 72 weeks, but the open-label trial enrolled a mixed-sex population and was not designed to select a male-specific winner.4
Your prescriber will weigh your medical history, current medications, goals, tolerance, follow-up data, and access. The detailed evidence belongs in the semaglutide versus tirzepatide comparison.
The cited trials do not provide a standard weight-loss rate for men. STEP 1 reported mean percentage change at 68 weeks, while SURMOUNT-1 and SURMOUNT-5 reported mean percentage change at 72 weeks.1,2,4
Those endpoints cannot be converted into a personal weekly schedule. Weight change may vary across treatment, and the overall trial averages came from mixed-sex populations.
Your first months of measurements give your prescriber the data needed to assess your response. The decision should use your trend instead of a rate taken from a group average.
The cited evidence cannot predict how long it would take you to lose 20 pounds. The trials reported average percentage changes at fixed endpoints. They did not report time to a fixed 20-pound target for men.1,2,4
Twenty pounds also represents a different percentage of body weight for each person. Converting the trial averages into a timeline would create a level of precision the studies do not support.
Record your baseline weight, body composition, and treatment goals with your prescriber. Your own first months of data will provide a safer basis for judging whether GLP-1 for men is working at an appropriate pace.
Weight alone cannot show whether a GLP-1 plan fits your health and goals. An Opt Health membership pairs 55+ biomarker testing with a physician who reads the results against your history and adjusts the plan after repeat labs every three to four months.
References
- Wilding JPH, Batterham RL, Calanna S, et al; STEP 1 Study Group. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. https://pubmed.ncbi.nlm.nih.gov/33567185/
- Jastreboff AM, Aronne LJ, Ahmad NN, et al; SURMOUNT-1 Investigators. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. https://pubmed.ncbi.nlm.nih.gov/35658024/
- Rentzeperi E, Pegiou S, Koufakis T, Grammatiki M, Kotsa K. Sex differences in response to treatment with glucagon-like peptide 1 receptor agonists: opportunities for a tailored approach to diabetes and obesity care. J Pers Med. 2022;12(3):454. https://pubmed.ncbi.nlm.nih.gov/35330453/
- Aronne LJ, Horn DB, le Roux CW, et al; SURMOUNT-5 Trial Investigators. Tirzepatide as compared with semaglutide for the treatment of obesity. N Engl J Med. 2025;393(1):26-36. https://pubmed.ncbi.nlm.nih.gov/40353578/
- Look M, Dunn JP, Kushner RF, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes Obes Metab. 2025;27(5):2720-2729. https://pubmed.ncbi.nlm.nih.gov/39996356/
This content is for informational purposes and does not replace evaluation, diagnosis, or treatment by a qualified medical professional.
Start Today
Your health, your terms. Discover how personalized care can transform not just the way you feel, but how you live.